AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
CRISIL Ratings Limited, the Monitoring Agency, has confirmed that Akums Drugs and Pharmaceuticals has fully utilized the entire Rs 6,373.70 million net IPO proceeds as per the stated objects, with no deviations. The IPO (July 30 – August 1, 2024) raised Rs 6,800 million gross; after issue expenses of Rs 426.30 million, net proceeds were deployed across debt repayment (Rs 3,870 million), incremental working capital (Rs 550 million), inorganic acquisitions (Rs 278.70 million), and general corporate purposes (Rs 1,675 million). During Q1 FY26, the company used Rs 81.40 million from the acquisition object to reimburse part of the Rs 165.08 million purchase of adjacent land and building at SIDCUL, Haridwar from Life Medicare & Biotech Pvt. Ltd., approved by the Board on February 6, 2025. The remaining Rs 72.98 million sits in the public offer account for issue expenses.
This is a routine, compliance-driven filing with no negative signals — all IPO money has been deployed on schedule and exactly as promised to investors. Shareholders can take comfort that management has executed the IPO plan without deviations, and the Haridwar land acquisition supports future expansion capacity at Plant No. 3. No direct material impact on stock price is expected from this disclosure itself.